Biomarker-driven and molecular targeted therapies for colorectal cancers

Marta Schirripa; Stacey A. Cohen; Francesca Battaglin; Heinz Josef Lenz

doi:10.1053/j.seminoncol.2017.06.003

Biomarker-driven and molecular targeted therapies for colorectal cancers

Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz Josef Lenz

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.

Original language	English
Number of pages	9
Journal	Seminars in Oncology
Early online date	Jul 4 2017
DOIs	https://doi.org/10.1053/j.seminoncol.2017.06.003
Publication status	E-pub ahead of print - Jul 4 2017

Keywords

BRAF
CpG island methylator phenotype
HER2
Microsatellite instability
RAS

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1053/j.seminoncol.2017.06.003

Fingerprint Dive into the research topics of 'Biomarker-driven and molecular targeted therapies for colorectal cancers'. Together they form a unique fingerprint.

Cite this

@article{605c3281292e425597d9200489ab04dd,

title = "Biomarker-driven and molecular targeted therapies for colorectal cancers",

abstract = "Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.",

keywords = "BRAF, CpG island methylator phenotype, HER2, Microsatellite instability, RAS",

author = "Marta Schirripa and Cohen, {Stacey A.} and Francesca Battaglin and Lenz, {Heinz Josef}",

year = "2017",

month = jul,

day = "4",

doi = "10.1053/j.seminoncol.2017.06.003",

language = "English",

journal = "Seminars in Oncology",

issn = "0093-7754",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Biomarker-driven and molecular targeted therapies for colorectal cancers

AU - Schirripa, Marta

AU - Cohen, Stacey A.

AU - Battaglin, Francesca

AU - Lenz, Heinz Josef

PY - 2017/7/4

Y1 - 2017/7/4

N2 - Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.

AB - Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.

KW - BRAF

KW - CpG island methylator phenotype

KW - HER2

KW - Microsatellite instability

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=85028323875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028323875&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2017.06.003

DO - 10.1053/j.seminoncol.2017.06.003

M3 - Article

AN - SCOPUS:85028323875

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

ER -